Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.

Published in:

Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1086028

By:

• Santiago-Setien, Pilar;
• Barquín-Rego, Cristina;
• Hernández-Martínez, Paula;
• Ezquerra-Marigomez, María;
• Torres-Barquin, Marta;
• Menéndez-Garcia, Cristina;
• Uriarte, Fernando;
• Jiménez-López, Yésica;
• Misiego, Mercedes;
• Sánchez de la Torre, Jose Ramón;
• Setien, Sonia;
• Delgado-Alvarado, Manuel;
• Riancho, Javier

Publication type:

Article